Frank Grosveld

USPTO Granted Patents = 12 (Patent Applications = 5)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 2.5

ph-index = 7

Forward Citations = 90(Granted Patents)

Company Filing History:

7 out of 17

Erasmus University Medical Center

patents

4 out of 13

Surface Oncology, Inc.

patents

2 out of 20

Erasmus Universiteit Rotterdam

patents

4. 2 out of 3

Harbour Biomed (shanghai) Co., Ltd.

patents

5. 1 out of 1

Erasmus Universiteit Medisch Centrum Rotterdam

patent

6. 1 out of 3

Minos Biosystems Limited

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240905 - Antibodies binding CTLA-4 and uses thereof (2025-03-04),

2. 11098122 - Antibodies binding CTLA-4 and uses thereof (2021-08-24),

3. 10934575 - Method for analysing the interaction of nucleotide sequences in a three-dimensional DNA structure (2021-03-02),

4. 10570201 - Anti-CD47 antibodies and methods of use (2020-02-25),

5. 10442858 - Anti-CD47 antibodies and methods of use (2019-10-15),

6. 9803016 - Anti-CD47 antibodies and methods of use (2017-10-31),

7. 9650441 - Anti-CD47 antibodies and methods of use (2017-05-16),

8. 8642295 - Circular chromosome conformation capture (4C) (2014-02-04),

9. 8507748 - Method for the production of a single heavy chain antibody (2013-08-13),

10. 8502014 - Method for the production of a single heavy chain antibody (2013-08-06),

11. 8153373 - Capture and characterized co-localized chromatin (4C) technology (2012-04-10),

12. 7709696 - Transgenic mice generated by transposition and uses thereof (2010-05-04),

Title: Frank Grosveld: Innovator in Monoclonal Antibodies

Introduction

Frank Grosveld is a prominent inventor based in Rotterdam, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 12 patents to his name, Grosveld's work has the potential to impact the treatment of various diseases, including cancers and autoimmune disorders.

Latest Patents

Among his latest patents is a groundbreaking invention related to antibodies binding to CTLA-4. This patent discloses isolated monoclonal antibodies that comprise a CD152-binding domain, specifically targeting human CD152. The methods outlined in this patent detail how these antibodies can be utilized to treat diseases, including cancers and autoimmune diseases. This innovative approach showcases Grosveld's commitment to advancing medical science through his research.

Career Highlights

Frank Grosveld has had a distinguished career, working with esteemed institutions such as Erasmus University Medical Center and Surface Oncology, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in biotechnology.

Collaborations

Throughout his career, Grosveld has worked alongside notable colleagues, including Jonathan Hill and Pamela M. Holland. These collaborations have further enriched his research and have played a crucial role in the development of his patented technologies.

Conclusion

Frank Grosveld's innovative work in monoclonal antibodies exemplifies the impact of dedicated research in biotechnology. His contributions continue to pave the way for new treatments and therapies that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.